In: Aura Biosciences

Aura Biosciences presents Interim Phase 1b/2 Data at the ASRS Annual Meeting
26/07/2018

  Aura Biosciences Presents Interim Phase 1b/2 Data at the American Society of Retina Specialists (ASRS) Annual Meeting CAMBRIGE. USA. July... Read More
Aura Biosciences announces Update of Clinical Safety Efficacy
20/06/2018

  Aura Biosciences Announces Update of Clinical Safety and Efficacy Data on Lead Candidate AU-011 for Choroidal Melanoma CAMBRIGE. USA. June... Read More
Aura Biosciences Completes $30 Million Series C Financing
26/12/2017

CAMBRIDGE. 21 December 2017– Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer…

Read More
Aura Biosciences announces Interim Phase 1b/2 Data on Light-Activated AU-011 for Primary Ocular Melanoma
14/11/2017

Light-activated viral nanoparticle for treatment of choroidal melanoma meets early study endpoints NEW ORLEANS. USA. 12 November 2017— Choroidal melanoma has... Read More
New Clinical Data from Aura Biosciences to be Featured in Presentation at the American Academy of Ophthalmology 2017 Annual Meeting
26/10/2017

Aura Biosciences announced a late-breaking session in AAO 2017 to highlight Phase 1b Clinical Safety Study for the treatment of primary... Read More
Aura Biosciences Announces Initiation of Phase 1b Clinical Trial and Receipt of FDA Fast Track Designation for AU-011 for the Treatment of Primary Ocular Melanoma
30/03/2017

Aura Biosciences Announces Initiation of Phase 1b Clinical Trial and Receipt of FDA Fast Track Designation for AU-011 for the Treatment... Read More
Aura Biosciences Receives FDA Clearance of Investigational New Drug Application for Light-activated AU-011 for the Treatment of Ocular Melanoma
06/02/2017

Aura Biosciences Receives FDA Clearance of Investigational New Drug Application for Light-activated AU-011 for the Treatment of Ocular Melanoma Cambridge, USA,... Read More
Aura Bioscience Inc. closes out a new round of $8M of funding
18/10/2016

Cambridge, USA, 18th October 2016 – In September Aura Bioscience Inc. (Aura) closed out a funding round worth 8 million dollars led by…

Read More
Aura Biosciences Secures $8 Million in Additional Funding and Augments Board of Directors and Clinical Advisory Board
29/09/2016

Cambridge, USA, 29th September 2016 – Aura Biosciences, a biotechnology company developing a new class of therapies to target and selectively destroy cancer cells…

Read More